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APC = antigen-presenting cell; CTL = cytotoxic T lymphocyte; DC = dendritic cell; GM-CSF = granulocyte-macrophage colony stimulating factor;
IFN = interferon; IL = interleukin; MHC = major histocompatibility complex; TAA = tumour-associated antigen; Th = T helper.
Available online http://breast-cancer-research.com/content/3/6/399
Introduction
There has been renewed interest in tumour immunother-
apy during the past decade. Vaccine immunotherapy for
cancer has been based on antigens against which
humoral and/or cellular responses are elicited. These anti-
gens should ideally be exclusively expressed or over-
expressed by the tumour and have been termed
tumour-associated antigens (TAAs). TAAs can be: prod-
ucts of genetic mutations; viral antigens associated with
the tumour; cancer-testis antigens that are normal proteins
expressed during development and then only in the testis
and tumours; normal proteins that are overexpressed in
tumours but restricted to specific tissues (differentiation
antigens); and proteins overexpressed in tumours but
present in many normal tissues. With the exception of anti-
bodies directed against growth factor receptors on cancer
cells (see the review article on herceptin in this issue [1]),
antibodies have had little impact on the growth of solid
tumours. Most of the efforts have therefore been focused
on the cellular immune response and the identification of
antigens recognized by human T lymphocytes.
Few TAAs have been identified for breast cancer, and they
generally correspond to differentiation antigens or over-
expressed normal proteins. Potential new target antigens
have recently been described for breast cancer [2], but
most of them are expressed on only a small percentage of
breast cancers. One of the first TAAs described for breast
cancer was HER2/neu, a 185 kDa transmembrane glyco-
protein and member of the epidermal growth factor recep-
tor family. Amplification and/or overexpression of
HER2/neu have been reported in 10–40% of primary
breast cancers, and also in ovarian, renal, gastric and
colorectal carcinomas. In this review, we shall focus on the
identification and application of HER2/neu peptides as
tumour vaccines for T cell recognition.
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Abstract
During the past decade there has been renewed interest in the use of vaccine immunotherapy for the
treatment of cancer. This review focuses on HER2/neu, a tumour-associated antigen that is over-
expressed in 10–40% of breast cancers and other carcinomata. Several immunogenic HER2/neu
peptides recognized by T lymphocytes have been identified to be included in cancer vaccines. Some of
these peptides have been assessed in clinical trials of patients with breast and ovarian cancer. Although
it has been possible to detect immunological responses against the peptides in the immunized patients,
no clinical responses have so far been described. Immunological tolerance to self-antigens like
HER2/neu may limit the functional immune responses against them. It will be of interest to determine
whether immune responses against HER2/neu epitopes can be of relevance to cancer treatment.
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Why peptide vaccines?
Cancer vaccines can be based either on whole cancer
cells or on TAAs. A recent report using autologous cancer
cells fused to dendritic cells (DCs) seems promising [3],
but this approach can be restricted by the low number of
tumour cells obtained from some solid tumours (e.g.
breast cancer), and also by the potential induction of
autoimmunity against non-TAAs. The isolation of tumour
cells and the generation of DCs are also both laborious
and expensive.
TAA-based cancer vaccines have included recombinant
virus expressing whole TAAs, or immunogenic peptides
derived from the TAAs. Such recombinant viruses have
generated weak responses, probably due to the presence
of neutralizing antibodies against the viruses. In contrast,
the use of peptide vaccines has produced significant clini-
cal responses in patients with advanced melanoma,
including total tumour regressions [4]. Peptides are rela-
tively easy and cheap to produce in large quantities.
Peptide vaccines also allow the inclusion of subimmuno-
dominant epitopes.
Peptide-based immunotherapies include vaccine formula-
tions to directly immunize patients, or the stimulation and
expansion of peptide-specific cytotoxic T lymphocytes
(CTLs) in vitro to be administered to patients in a method
called adoptive transfer. Peptide vaccines can include the
peptides for both MHC class I and class II molecules.
They can be administered directly to the patient or used to
pulse DCs ex vivo prior to re-infusion [4].
Identification of immunogenic HER2/neu
peptides
CD8+ CTLs and CD4+ Th cell lymphocytes recognize anti-
gens presented as small peptides in the groove of MHC
molecules. Peptides bound to MHC class I and class II
molecules are usually 8–10 and 15 amino acids in length,
respectively. Some of the peptide residues are buried in
the MHC groove and act as anchor residues, which define
binding motifs specific for different MHC alleles. These
binding motifs can be used to identify potential MHC-
binding peptides from a given protein. Although peptides
can bind MHC molecules, this does not mean that they
are presented on the cell surface. Proteins are degraded
intracellularly in the cytosol by the proteasome complex for
presentation by MHC class I molecules, and degraded in
endosomes for presentation by MHC class II molecules.
Not all the putative MHC-binding peptides from a protein
are generated in vivo and it is not currently possible to
predict which peptides will be naturally processed. In the
case of peptides binding MHC class I molecules, different
cells (e.g. antigen-presenting cells [APCs] like DCs and
tumour cells) can have different proteasome complexes
that may generate different peptides from the same
protein. It has been shown that some TAA epitopes are
generated by tumour cells but not by DCs [5]. For these
TAA epitopes, peptide-based vaccines may be the only
formulation for vaccination.
Two approaches have been used to identify immunogenic
peptides recognized by CTLs. First, tumour-specific CTL
lines or clones have been generated using tumour infiltrat-
ing lymphocytes and autologous tumour cells. Target cells
pulsed with the peptides are then used to stimulate these
CTL lines or clones and identify peptide-specific T cell
reactivity. This method has the advantage of there being a
guarantee that peptides identified in this way are naturally
processed. It is not easy, however, to obtain tumour infil-
trating lymphocytes and sufficient autologous tumour cells
from many tumours, including breast cancer.
The second approach of identity is known as ‘reverse
immunology’. In this technique, CTLs are generated by
pulsing APCs with peptides. It is then necessary to deter-
mine whether the peptide-specific CTLs are able to recog-
nize whole cells expressing the antigen. If the
peptide-specific CTLs do not recognize tumour cells
expressing the whole protein, this suggests that the
peptide may not be naturally processed and presented. A
similar approach has been used to identify immunogenic
peptides binding MHC class II molecules. Using these
techniques, several immunogenic peptides have been
identified for the HER2/neu protein that are naturally
processed and presented (Table 1).
T cell responses after stimulation with
HER2/neu peptides in vitro
CTLs specific for HER2/neu peptides have been
described, but they have not always recognized endoge-
nously processed peptides on the cell surface [6]. Even
where such reactivity has been demonstrated [7], the con-
centrations of HER2/neu peptides necessary for CTL
recognition were at least two orders of magnitude higher
than those required for viral proteins. In the case of helper
T cells generated against HER2/neu peptides, only low
affinity T cells have been found, even when using proto-
cols that generated high affinity T cells for viral antigens
[8]. These results suggest there could be some degree of
tolerance to HER2/neu protein. Immunological tolerance
to normal proteins expressed at low levels in normal
tissues and overexpressed in tumours (e.g. HER2/neu) is
a concern for the application of these TAAs in
immunotherapy [9]. Deletion or anergy of high avidity T
cells can occur and only low affinity T cells may be
present. It is of interest to know whether it is possible to
generate functional T cells with high affinity for HER2/neu
epitopes and also whether low affinity cells are relevant for
the clearance of tumour cells in vivo. A study has shown
that whereas low avidity CTLs can be readily detected by
standard immunological assays, only high avidity CTLs
exert biological function in vivo in tumour models [10].c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
r
e
s
e
a
r
c
h
 
a
r
t
i
c
l
e
As described earlier, not all of the CTL lines or clones spe-
cific for HER2/neu peptides are able to recognize target
cells expressing the antigen [6]. Once it has been demon-
strated that the peptide is naturally processed and that T
cells are of high affinity, a different explanation is available.
This is that the conformation of the MHC–peptide
complex when the peptide is loaded extracellularly to gen-
erate the CTLs is different to that of the MHC–peptide
complex synthesized within the cells. For example, CD4+ T
cell hybridomas isolated from mice immunized with a syn-
thetic peptide identical to a dominant and naturally
processed I-Ak-restricted peptide from hen lysozyme were
not able to recognize the antigen after processing by dif-
ferent APCs [11]. This possibility represents a concern for
peptide-based immunotherapies.
Clinical trials with HER2/neu peptides
Most published clinical trials have used HER2/neu peptide
HER2 369-377, which binds MHC class I molecules. All
the trials have demonstrated no toxicity from treatment, but
there are few data to demonstrate their effectiveness.
In a phase I study [6], four patients with metastatic breast,
ovarian or colorectal cancer were immunized with peptide
HER2 369-377 in incomplete Freund’s adjuvant. There
were no clinical responses. Peptide-specific CTLs were
obtained from blood after immunization and two re-stimu-
lations with peptide in vitro in 3/4 patients. However, none
of these CTL lines or clones recognized tumour cells
expressing HER2/neu, even when they were able to rec-
ognize target cells that had been pulsed with 1 ng/ml
(10–9 M) peptide. A similar protocol in patients with
melanoma had produced peptide-specific CTLs that were
able to kill melanoma cells in vitro [6].
HER 369-377 peptide was administered with granulocyte-
macrophage colony stimulating factor (GM-CSF) in a dif-
ferent phase I study. Three out of nine patients showed
proliferative T cell responses to peptide in vitro, and 7/8
patients gave a delayed-type hypersensitivity response to
peptide. No clinical responses were observed. CTL pre-
cursors were detected in only one patient who was in
complete remission before the immunization, having
remained free of disease 12 months after receiving a bone
marrow transplant [12].
Using a different approach, six patients with advanced
breast or ovarian cancer were injected subcutaneously
Available online http://breast-cancer-research.com/content/3/6/399
Table 1
Immunogenic peptides derived from HER2/neu protein that are naturally processed and presented
MHC Peptide Sequence Reference
HLA-A*0201 HER2 5-13 ALCRWGLLL [19]
HER2 106-114 QLFEDNYAL [20]
HER2 369-377 KIFGSLAFL [7,19–21]
HER2 435-443 ILHNGAYSL [19,22]
HER2 654-662 IISAVVGIL [23]
HER2 665-673 VVLGVVFGI [22]
HER2 689-697 RLLQETELV [20]
HER2 773-782 VMAGVGSPYV [21]
HER2 789-797 CLTSTVQLV [7]
HER2 799-807 QLMPYGCLL [7]
HER2 835-842 YLEDVRLV [7]
HER2 851-859 VLVKSPNHV [7]
HER2 952-961 YMIMVKCWMI [22]
HER2 971-979 ELVSEFSRM [7]
HLA-A*0301† HER2 754-762 VLRENTSPK [24]
HLA-A*2402 HER2 8-16 RWGLLLALL [25]
HER2 63-71 TYLPTNASL [26]
HER2 780-788 PYVSRLLGI [27]
HLA-DR1, DR4, DR52, DR53 HER2 883-899 KVPIKWMALESILRRRF [8]
MHC, Major histocompatibility complex. † Also binds to three other alleles of the HLA-A3 superfamily: A*1101, A*3101 and A*3301.with DCs pulsed with HER2 369-377 and HER2 654-662
peptides [13]. After three vaccinations, HER2 369-377
peptide-specific T cells were detected in blood in two of
the patients using intracellular staining for IFN-γ. These T
cells were able to kill targets pulsed with the peptide, and
also lysed tumour cells expressing HER2/neu. One of the
two patients showed stable disease of longer than 8
months duration, having had progressive disease before
the vaccination and a debulking surgery.
In two other phase I studies, longer HER2 peptides
(15–18 amino acids) were used, corresponding to puta-
tive Th cell sequences [14,15]. No evidence was provided
that the peptides actually bind MHC class II molecules. In
one study, eight patients with stage III or IV breast or
ovarian cancer were immunized with HER2/neu peptides
corresponding to the extracellular domain of the protein
(HER2 42-56, HER2 98-114 and HER2 328-345), or with
peptides corresponding to the intracellular domain of the
protein (HER2 776-790, HER2 927-941 and HER2
1166-1180). Peptides were administered with GM-CSF
[14]. Proliferative responses were detected against the
peptides and sometimes against the recombinant protein.
No correlation between the response and the MHC haplo-
type of the patient was observed. Cytotoxicity or clinical
responses to treatment were not reported.
In the other phase I study, 19 patients with stage IV breast
or ovarian cancer were immunized with three HER2/neu
peptides plus GM-CSF [15]. The peptides, corresponding
to sequences HER2 369-384, HER2 688-703 and HER2
971-984, each contained a putative HLA-A2 binding
motif. After immunization, 83% of the patients had prolifer-
ative responses to at least one of the peptides and some
of them also showed proliferative responses to recombi-
nant parts of HER2/neu. In some patients there was also
an increase in the number of T cell precursors specific for
the nonamer contained within the immunizing peptides.
However, limited cytotoxicity of target cells expressing the
antigen was observed (18% killing of SKOV3-A2 with
clone anti-HER2 369-377 peptide, and 25% killing of
Epstein-Barr virus-transformed lymphoblastoid B cells
transfected with HER2/neu versus 12% in untransfected
cells). Clinical response to treatment was not reported.
Clinical relevance of immune responses
induced against HER2/neu peptides
The aforementioned clinical studies have shown that it is
possible to induce immunological responses against
HER2/neu peptides in patients with cancer, but no clinical
responses have been reported. The fact that a tumour
antigen elicits a tumour-specific response does not neces-
sarily mean that the immune response will cause killing of
the tumour in vivo. A central aim of future research must
first be to establish whether those responses measured in
vitro are of relevance for the clearance of established
tumours in vivo and, second, to establish which, if any,
parameters measured in vitro correlate best with a protec-
tive immunological response in vivo. The assessment of
the immune response in immunized patients is often
limited to circulating or lymph node lymphocytes rather
than lymphocytes at the tumour site. In a study of patients
with advanced melanoma, immunization with an anchor
residue-modified peptide from gp100 stimulated strong
responses in most patients, yet no clinical responses were
seen [16]. In contrast, patients who also received IL-2
exhibited reduced CTL activities in vitro but significant
clinical responses were also observed [16]. A similar
observation was made in another study with melanoma
patients immunized with a peptide from MAGE-3; signifi-
cant tumour regression was reported in some patients but
with no evidence for a CTL response in their blood [17].
Conclusion
Several immunogenic peptides derived from HER2/neu
have been identified and T cells specific for these pep-
tides have been generated in vitro and in vivo. The next
steps will be to establish whether these HER2/neu-
specifc T cells are of relevance for the clearance of
tumours in vivo and, if so, what is the best immunization
protocol to generate and mobilize such T cells.
Finally, we should not forget that tumour cells can down-
regulate MHC class I expression [18], potentially limiting
the efficacy of immunotherapies based on immunogenic
peptides for T cell responses.
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